<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793818</url>
  </required_header>
  <id_info>
    <org_study_id>EVATAT</org_study_id>
    <nct_id>NCT01793818</nct_id>
  </id_info>
  <brief_title>Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein</brief_title>
  <acronym>EVATAT</acronym>
  <official_title>Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIOSANTECH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BIOSANTECH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tat Oyi vaccination on seropositive patients could help their immune system to recognize and
      neutralize Tat. The neutralization of extra cellular Tat should help the cellular immune
      response to eliminate HIV-1 infected cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol got a favorable judgment from an ethic committee (CPP SudMed 2) on November 9th,
      2012 and was authorized by the French drug agency (ANSM) on January 24th, 2013. It will be
      proposed to HIV-1 infected volunteers to participate to a phase I/II clinical trial to test
      the Tat Oyi vaccine. Volunteers will have an undetectable viremia (lower than 40 copies/ml)
      and a level of CD4 cells higher than 350 /mm3 since at least one year under Anti Retroviral
      Treatment (ART). It will be a randomized double blinded clinical trial with a placebo.

      Main Objective: No undesirable events due to vaccination and viremia remaining &lt; 100
      copies/ml after interruption of cART.

      Secondary objective: An immune response against Tat characterized by the cross recognition of
      Tat variants representative of the five main HIV-1 clades.

      Main parameter of evaluation: Plasma viremia. Secondary parameter of evaluation: Detection
      with ELISA of antibodies able to recognize Tat variants representative of the five main HIV-1
      clades.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal vaccine dose (phase I/II)</measure>
    <time_frame>Two years</time_frame>
    <description>No undesirable events due to vaccination and viremia remaining &lt; 100 copies/ml after interruption of ART.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal Vaccine Dose (phase I/II)</measure>
    <time_frame>Two years</time_frame>
    <description>An immune response against Tat characterized by the cross recognition of Tat variants representative of the five main HIV-1 clades.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Group 1 Phase I/II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three injections with no active principle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Phase I/II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three injections of Tat Oyi vaccine containing 11 µg of active principle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Phase I/II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three injections Tat Oyi vaccine containing 33 µg of active principle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Phase I/II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three injections Tat Oyi vaccine containing 99 µg of active principle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tat Oyi</intervention_name>
    <description>Three injections in the arm</description>
    <arm_group_label>Group 1 Phase I/II</arm_group_label>
    <arm_group_label>Group 2 Phase I/II</arm_group_label>
    <arm_group_label>Group 3 Phase I/II</arm_group_label>
    <arm_group_label>Group 4 Phase I/II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 64 years old for the pre inclusion visit.

          -  Documented HIV-1 Infection

          -  Preferentially, group A patients from CDC classification but no group C patients.

          -  HIV-1 patients treated with three antiretroviral drugs since 12 months not changed
             since three months and having an undetectable viremia since 12 months.

          -  HIV-1 Chronic infection defined by a positive HIV-1 ELISA and HIV-1 proteins
             characterized in a full HIV-1 Western blot. Stable undetectable plasmatic HIV RNA
             (lower than 40 copies/ml) since 12 months. Lymphocyte CD4 cells higher than 350/mm3
             with a NADIR higher than 200/mm3 since 12 months.

          -  Free engagement, fully explained and wrote with the patient signature for the
             inclusion visit and before any test required for the clinical trial.

          -  Patient affiliated to a social security system.

          -  No vaccination against influenza or other pathogens since three months.

          -  No chemotherapy or treatments with corticosteroid

          -  HIV-1 patients being abstinent former drug users or drug users following substitution
             training.

        Exclusion Criteria:

          -  HIV-1 patient protected regarding French law (articles L1121-5, L1121-6, L1121-7,
             L1121-8 &amp; L1122-2)

          -  No HIV-1 infection

          -  Patient infected with HIV-2

          -  Patient in HIV-1 primo infection or recently in primo infection

          -  Patient in symptomatic primo infection or CD4 cells lower than 200/mm3

          -  Women sexually active with no efficient contraception

          -  Pregnant women or brass feeding.

          -  Patient with an opportunistic infection in the CDC group C.

          -  Patient with a cancer and/or under chemotherapy or radiotherapy.

          -  Patient with an evolutive psychiatric pathology

          -  Patient being HBV and/or HCV positive

          -  Patient being ELISA positive for HTLV-1

          -  Patient being cirrhotic (Child and Pugh level A, B and C)

          -  Patient under criminal investigation

          -  Patients with abnormal blood formulation

          -  Patient participating to another clinical research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Ravaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique - Universitary Hospital Centre Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Loret E. HIV extracellular Tat: myth or reality? Curr HIV Res. 2015;13(2):90-7. Review.</citation>
    <PMID>25439235</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Tat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data base (HIV RNA, CD4, CD8, HIV DNA, Tat immune response) and statistical analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

